Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to $14.6 million.

  • Korro Bio's Total Current Liabilities rose 755.33% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 755.33%. This contributed to the annual value of $15.0 million for FY2024, which is 2321.51% down from last year.
  • As of Q3 2025, Korro Bio's Total Current Liabilities stood at $14.6 million, which was up 755.33% from $17.2 million recorded in Q2 2025.
  • Korro Bio's 5-year Total Current Liabilities high stood at $22.0 million for Q1 2023, and its period low was $8.3 million during Q2 2023.
  • For the 5-year period, Korro Bio's Total Current Liabilities averaged around $13.9 million, with its median value being $12.9 million (2025).
  • As far as peak fluctuations go, Korro Bio's Total Current Liabilities plummeted by 7806.15% in 2021, and later soared by 12391.68% in 2023.
  • Korro Bio's Total Current Liabilities (Quarter) stood at $11.4 million in 2021, then fell by 23.87% to $8.7 million in 2022, then skyrocketed by 123.92% to $19.5 million in 2023, then fell by 23.22% to $15.0 million in 2024, then dropped by 2.15% to $14.6 million in 2025.
  • Its Total Current Liabilities stands at $14.6 million for Q3 2025, versus $17.2 million for Q2 2025 and $12.9 million for Q1 2025.